Ozempic Gastroparesis Settlement: Criteria Explained

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health to Occupational Exposure Awareness

The legacy domain of general health and science information has historically provided broad, accessible content on wellness, disease prevention, and medical advancements. This foundation served a wide audience seeking reliable, non-specialized knowledge. However, as public health discourse evolves, specific therapeutic exposures and their downstream consequences demand more targeted attention. One such area involves the transition from general metabolic health discussions to the nuanced risks associated with glucagon-like peptide-1 receptor agonist use, particularly in mass production contexts where drug exposure may occur occupationally. In manufacturing environments, workers handling active pharmaceutical ingredients face distinct considerations that differ from patient populations. The shift from general health literacy to occupational exposure awareness requires examining how bulk production processes might introduce unique risk profiles. For instance, personnel involved in synthesizing, formulating, or packaging medications like semaglutide may encounter concentrations or routes of exposure not typical for end users. This pivot necessitates a focus on workplace safety protocols, monitoring practices, and potential long-term health implications—without delving into specific disease mechanisms. The transition thus moves from broad health education to a more granular, industry-specific lens, emphasizing the importance of understanding exposure pathways in mass production settings while maintaining a neutral, evidence-informed perspective.

Bridging to Clinical Evidence: Ozempic and Gastroparesis

Building on the occupational exposure framework, it is essential to examine the clinical evidence linking Ozempic (semaglutide) to gastroparesis. Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and nutritional status. Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). GLP-1 receptor agonists work by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. This pharmacological effect on gastric motility is central to the mechanistic pathway linking Ozempic to gastroparesis. By delaying gastric emptying, Ozempic can exacerbate or unmask gastroparesis in susceptible individuals, leading to clinical symptoms that may persist beyond the intended therapeutic effect.

Clinical Trial Evidence and Gastrointestinal Adverse Reactions

Clinical trial data demonstrate a clear association between Ozempic use and gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In trials with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these trial data, the spectrum of reported gastrointestinal symptoms—particularly nausea, vomiting, dyspepsia, and gastroesophageal reflux—are consistent with gastroparesis presentation.

Adequacy of Warnings and Settlement Considerations

The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk consideration. The prescribing information for Ozempic does not specifically mention gastroparesis as a potential adverse reaction. Instead, it describes gastrointestinal adverse reactions in general terms, noting that they occur more frequently with Ozempic than placebo and that most occur during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The label also includes limitations of use, stating that Ozempic has not been studied in patients with a history of pancreatitis and that other antidiabetic therapies should be considered in such patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, no similar warning exists for patients with pre-existing gastroparesis or those at risk for delayed gastric emptying. This gap in specific warnings may affect settlement considerations for affected patients, as it raises questions about whether the manufacturer adequately informed prescribers and patients of the risk of developing gastroparesis or exacerbating underlying gastric motility disorders. Settlement-related considerations for patients who developed gastroparesis after using Ozempic involve several factors. First, the timeline between exposure and documented harm is important. Gastrointestinal adverse reactions, including those consistent with gastroparesis, often occur during dose escalation, as noted in clinical trials (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, symptoms may also develop after prolonged use or after dose increases. Patients who experienced persistent nausea, vomiting, or other gastroparesis symptoms that required medical evaluation or hospitalization may have a stronger basis for a claim. Second, the severity and duration of harm matter. Gastroparesis can lead to malnutrition, weight loss, electrolyte imbalances, and decreased quality of life. Patients who required interventions such as dietary modifications, prokinetic medications, or even gastric electrical stimulation may have more significant damages. Third, the adequacy of medical records documenting the diagnosis of gastroparesis, the timing of Ozempic use, and the exclusion of other causes is essential for establishing causation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism of action. This can exacerbate or unmask gastroparesis in susceptible individuals, leading to symptoms like nausea, vomiting, and bloating. Clinical trials show higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does the Ozempic label warn about gastroparesis?

No, the prescribing information for Ozempic does not specifically mention gastroparesis as a potential adverse reaction. It describes gastrointestinal adverse reactions in general terms and notes that most occur during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This lack of specific warning may be relevant for settlement evaluations.

What factors are considered in Ozempic gastroparesis settlement criteria?

Key factors include the timeline between Ozempic exposure and documented gastroparesis diagnosis, severity and duration of harm (e.g., malnutrition, hospitalization), and adequacy of medical records establishing causation. Patients who experienced persistent symptoms during dose escalation or after prolonged use may have stronger claims.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.